Author

Stephen L. DeAngelo

University of MichiganORCID 0000-0002-7984-5780Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Andrii BaliaiD· 1 shared Cristina CastilloiD· 1 shared Elizabeth C. McCullaiD· 1 shared Hannah Noelle BelliD· 1 shared Indrani TalukderiD· 1 shared Jianping HeiD· 1 shared João A. PauloiD· 1 shared Joseph Douglas ManciasiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrii BaliaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in colorectal cancer

Stephen L. DeAngelo, Liang Zhao, Sofia Dziechciarz, Myungsun Shin, Sumeet A. Solanki, Andrii Balia, Marwa O. El-Derany, Cristina Castillo, Yao Qin, Nupur Kanti Das, Hannah Noelle Bell, João A. Paulo, Yuezhong Zhang, Nicholas J. Rossiter, Elizabeth C. McCulla, , Yatrik Madhukar Shah

This study recharacterizes RSL3 as a broad selenoprotein inhibitor, showing its potential as a therapeutic target for colorectal cancer by inducing ferroptosis.

Cancer Research · May 19, 2025Peer-reviewedCancer Biology